Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00269061 · ClinicalTrials.gov registry record · Phase 1
Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00269061 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 32 participants.
The verdict
NCT00269061, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will use Magnetic Resonance Imaging (MRI) techniques to evaluate changes in fluid volume in the lower legs of diabetic patients who add either pioglitazone or placebo to their current diabetic regimen.
Interventions
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00269061
The ClinicalTrials.gov registry entry for NCT00269061 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pioglitazone is the first listed.
NCT00269061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00269061 about?
NCT00269061 is a clinical study titled "Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin". This study will use Magnetic Resonance Imaging (MRI) techniques to evaluate changes in fluid volume in the lower legs of diabetic patients who add either pioglitazone or placebo to their current diabetic regimen.
What is the current status of trial NCT00269061?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-01.
What interventions are being tested in trial NCT00269061?
The interventions under investigation include: pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00269061?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.